Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

A Trp53fl/flPtenfl/fl mouse model of undifferentiated pleomorphic sarcoma mediated by adeno-Cre injection and in vivo bioluminescence imaging.

Buchakjian MR, Merritt NM, Moose DL, Dupuy AJ, Tanas MR, Henry MD.

PLoS One. 2017 Aug 25;12(8):e0183469. doi: 10.1371/journal.pone.0183469. eCollection 2017.

2.

Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.

Bodle CR, Mackie DI, Hayes MP, Schamp JH, Miller MR, Henry MD, Doorn JA, Houtman JCD, James MA, Roman DL.

J Nat Prod. 2017 Jul 28;80(7):1992-2000. doi: 10.1021/acs.jnatprod.7b00112. Epub 2017 Jun 16.

3.

Inhibiting G protein βγ signaling blocks prostate cancer progression and enhances the efficacy of paclitaxel.

Paudyal P, Xie Q, Vaddi PK, Henry MD, Chen S.

Oncotarget. 2017 May 30;8(22):36067-36081. doi: 10.18632/oncotarget.16428.

4.

CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer.

Zoni E, Chen L, Karkampouna S, Granchi Z, Verhoef EI, La Manna F, Kelber J, Pelger RCM, Henry MD, Snaar-Jagalska E, van Leenders GJLH, Beimers L, Kloen P, Gray PC, van der Pluijm G, Kruithof-de Julio M.

Oncogene. 2017 Aug 17;36(33):4739-4749. doi: 10.1038/onc.2017.87. Epub 2017 Apr 10.

5.

α3β1 Integrin Suppresses Prostate Cancer Metastasis via Regulation of the Hippo Pathway.

Varzavand A, Hacker W, Ma D, Gibson-Corley K, Hawayek M, Tayh OJ, Brown JA, Henry MD, Stipp CS.

Cancer Res. 2016 Nov 15;76(22):6577-6587. doi: 10.1158/0008-5472.CAN-16-1483. Epub 2016 Sep 28.

6.

CD151 promotes α3β1 integrin-dependent organization of carcinoma cell junctions and restrains collective cell invasion.

Zevian SC, Johnson JL, Winterwood NE, Walters KS, Herndon ME, Henry MD, Stipp CS.

Cancer Biol Ther. 2015;16(11):1626-40. doi: 10.1080/15384047.2015.1095396. Epub 2015 Sep 29.

7.

Individualization of Adjuvant Therapy After Radical Prostatectomy for Clinically Localized Prostate Cancer: Current Status and Future Directions.

Mitchell DL, Tracy CR, Buatti JM, Smith MC, Snow AN, Henry MD, Vaena DA, Tewfik HH, Watkins JM.

Clin Genitourin Cancer. 2016 Feb;14(1):12-21. doi: 10.1016/j.clgc.2015.07.022. Epub 2015 Aug 6. Review.

PMID:
26341039
8.

Downregulation of dystroglycan glycosyltransferases LARGE2 and ISPD associate with increased mortality in clear cell renal cell carcinoma.

Miller MR, Ma D, Schappet J, Breheny P, Mott SL, Bannick N, Askeland E, Brown J, Henry MD.

Mol Cancer. 2015 Jul 30;14:141. doi: 10.1186/s12943-015-0416-z.

9.

Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis.

Reilly JE, Neighbors JD, Tong H, Henry MD, Hohl RJ.

Clin Exp Metastasis. 2015 Aug;32(6):555-66. doi: 10.1007/s10585-015-9727-0. Epub 2015 Jun 13.

10.

Alterations in cancer cell mechanical properties after fluid shear stress exposure: a micropipette aspiration study.

Chivukula VK, Krog BL, Nauseef JT, Henry MD, Vigmostad SC.

Cell Health Cytoskelet. 2015 Jan 9;7:25-35.

11.

From the NATO SOF Surgeon.

Henry MD.

J Spec Oper Med. 2015 Spring;15(1):132. No abstract available.

PMID:
27280264
12.

Loss of SOD3 (EcSOD) Expression Promotes an Aggressive Phenotype in Human Pancreatic Ductal Adenocarcinoma.

O'Leary BR, Fath MA, Bellizzi AM, Hrabe JE, Button AM, Allen BG, Case AJ, Altekruse S, Wagner BA, Buettner GR, Lynch CF, Hernandez BY, Cozen W, Beardsley RA, Keene J, Henry MD, Domann FE, Spitz DR, Mezhir JJ.

Clin Cancer Res. 2015 Apr 1;21(7):1741-51. doi: 10.1158/1078-0432.CCR-14-1959. Epub 2015 Jan 29.

13.

rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data.

Shen S, Park JW, Lu ZX, Lin L, Henry MD, Wu YN, Zhou Q, Xing Y.

Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):E5593-601. doi: 10.1073/pnas.1419161111. Epub 2014 Dec 5.

14.

The glycosyltransferase LARGE2 is repressed by Snail and ZEB1 in prostate cancer.

Huang Q, Miller MR, Schappet J, Henry MD.

Cancer Biol Ther. 2015;16(1):125-36. doi: 10.4161/15384047.2014.987078.

15.

Impact of prostate inflammation on lesion development in the POET3(+)Pten(+/-) mouse model of prostate carcinogenesis.

Burcham GN, Cresswell GM, Snyder PW, Chen L, Liu X, Crist SA, Henry MD, Ratliff TL.

Am J Pathol. 2014 Dec;184(12):3176-91. doi: 10.1016/j.ajpath.2014.08.021. Epub 2014 Nov 22.

16.

Transcriptome-wide landscape of pre-mRNA alternative splicing associated with metastatic colonization.

Lu ZX, Huang Q, Park JW, Shen S, Lin L, Tokheim CJ, Henry MD, Xing Y.

Mol Cancer Res. 2015 Feb;13(2):305-18. doi: 10.1158/1541-7786.MCR-14-0366. Epub 2014 Oct 1.

17.

Obesity-dependent dysregulation of glucose homeostasis in kinase suppressor of ras 2-/- mice.

Henry MD, Costanzo-Garvey DL, Klutho PJ, Lewis RE.

Physiol Rep. 2014 Jul 4;2(7). pii: e12053. doi: 10.14814/phy2.12053. Print 2014 Jul 1.

18.

Clinical relevance of optimizing vitamin D status in soldiers to enhance physical and cognitive performance.

Wentz LM, Eldred JD, Henry MD, Berry-Cabán CS.

J Spec Oper Med. 2014 Spring;14(1):58-66. Review.

PMID:
24604440
19.

Prolyl-4-hydroxylase 3 (PHD3) expression is downregulated during epithelial-to-mesenchymal transition.

Place TL, Nauseef JT, Peterson MK, Henry MD, Mezhir JJ, Domann FE.

PLoS One. 2013 Dec 18;8(12):e83021. doi: 10.1371/journal.pone.0083021. eCollection 2013.

20.

Integrin α3β1 can function to promote spontaneous metastasis and lung colonization of invasive breast carcinoma.

Zhou B, Gibson-Corley KN, Herndon ME, Sun Y, Gustafson-Wagner E, Teoh-Fitzgerald M, Domann FE, Henry MD, Stipp CS.

Mol Cancer Res. 2014 Jan;12(1):143-154. doi: 10.1158/1541-7786.MCR-13-0184. Epub 2013 Sep 3.

21.

Chronic chlorpyrifos exposure does not promote prostate cancer in prostate specific PTEN mutant mice.

Svensson RU, Bannick NL, Marin MJ, Robertson LW, Lynch CF, Henry MD.

J Environ Pathol Toxicol Oncol. 2013;32(1):29-39.

22.

High rates of pregnancy loss by subordinates leads to high reproductive skew in wild golden lion tamarins (Leontopithecus rosalia).

Henry MD, Hankerson SJ, Siani JM, French JA, Dietz JM.

Horm Behav. 2013 May;63(5):675-83. doi: 10.1016/j.yhbeh.2013.02.009. Epub 2013 Feb 27.

23.

Three-dimensional etching of silicon for the fabrication of low-dimensional and suspended devices.

Walavalkar SS, Homyk AP, Henry MD, Scherer A.

Nanoscale. 2013 Feb 7;5(3):927-31. doi: 10.1039/c2nr32981f. Epub 2013 Jan 4.

PMID:
23292113
24.

Resistance to fluid shear stress is a conserved biophysical property of malignant cells.

Barnes JM, Nauseef JT, Henry MD.

PLoS One. 2012;7(12):e50973. doi: 10.1371/journal.pone.0050973. Epub 2012 Dec 3.

25.

Integrin α3β1 regulates tumor cell responses to stromal cells and can function to suppress prostate cancer metastatic colonization.

Varzavand A, Drake JM, Svensson RU, Herndon ME, Zhou B, Henry MD, Stipp CS.

Clin Exp Metastasis. 2013 Apr;30(4):541-52. doi: 10.1007/s10585-012-9558-1. Epub 2012 Dec 6.

26.

Loss of LARGE2 disrupts functional glycosylation of α-dystroglycan in prostate cancer.

Esser AK, Miller MR, Huang Q, Meier MM, Beltran-Valero de Bernabé D, Stipp CS, Campbell KP, Lynch CF, Smith BJ, Cohen MB, Henry MD.

J Biol Chem. 2013 Jan 25;288(4):2132-42. doi: 10.1074/jbc.M112.432807. Epub 2012 Dec 6.

27.

Kinase suppressor of Ras 2 (KSR2) regulates tumor cell transformation via AMPK.

Fernandez MR, Henry MD, Lewis RE.

Mol Cell Biol. 2012 Sep;32(18):3718-31. doi: 10.1128/MCB.06754-11. Epub 2012 Jul 16.

28.

Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy.

Norian LA, Kresowik TP, Rosevear HM, James BR, Rosean TR, Lightfoot AJ, Kucaba TA, Schwarz C, Weydert CJ, Henry MD, Griffith TS.

PLoS One. 2012;7(2):e31085. doi: 10.1371/journal.pone.0031085. Epub 2012 Feb 1.

29.

Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer.

Svensson RU, Haverkamp JM, Thedens DR, Cohen MB, Ratliff TL, Henry MD.

Am J Pathol. 2011 Jul;179(1):502-12. doi: 10.1016/j.ajpath.2011.03.014. Epub 2011 May 7.

30.

Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle?

Nauseef JT, Henry MD.

Nat Rev Urol. 2011 Jun 21;8(8):428-39. doi: 10.1038/nrurol.2011.85. Review.

PMID:
21691304
31.

An inducible model of abacterial prostatitis induces antigen specific inflammatory and proliferative changes in the murine prostate.

Haverkamp JM, Charbonneau B, Crist SA, Meyerholz DK, Cohen MB, Snyder PW, Svensson RU, Henry MD, Wang HH, Ratliff TL.

Prostate. 2011 Aug 1;71(11):1139-50. doi: 10.1002/pros.21327. Epub 2011 Jan 12.

32.

The ARF tumor suppressor inhibits tumor cell colonization independent of p53 in a novel mouse model of pancreatic ductal adenocarcinoma metastasis.

Muniz VP, Barnes JM, Paliwal S, Zhang X, Tang X, Chen S, Zamba KD, Cullen JJ, Meyerholz DK, Meyers S, Davis JN, Grossman SR, Henry MD, Quelle DE.

Mol Cancer Res. 2011 Jul;9(7):867-77. doi: 10.1158/1541-7786.MCR-10-0475. Epub 2011 Jun 2.

33.

Down regulation of CSL activity inhibits cell proliferation in prostate and breast cancer cells.

Yong T, Sun A, Henry MD, Meyers S, Davis JN.

J Cell Biochem. 2011 Sep;112(9):2340-51. doi: 10.1002/jcb.23157.

PMID:
21520243
34.

Vinculin activators target integrins from within the cell to increase melanoma sensitivity to chemotherapy.

Nelson ES, Folkmann AW, Henry MD, DeMali KA.

Mol Cancer Res. 2011 Jun;9(6):712-23. doi: 10.1158/1541-7786.MCR-10-0599. Epub 2011 Apr 1.

35.

Tunable visible and near-IR emission from sub-10 nm etched single-crystal Si nanopillars.

Walavalkar SS, Hofmann CE, Homyk AP, Henry MD, Atwater HA, Scherer A.

Nano Lett. 2010 Nov 10;10(11):4423-8. doi: 10.1021/nl102140k. Epub 2010 Oct 4.

PMID:
20919695
36.

ZEB1 coordinately regulates laminin-332 and {beta}4 integrin expression altering the invasive phenotype of prostate cancer cells.

Drake JM, Barnes JM, Madsen JM, Domann FE, Stipp CS, Henry MD.

J Biol Chem. 2010 Oct 29;285(44):33940-8. doi: 10.1074/jbc.M110.136044. Epub 2010 Aug 21.

37.

Ga(+) beam lithography for nanoscale silicon reactive ion etching.

Henry MD, Shearn MJ, Chhim B, Scherer A.

Nanotechnology. 2010 Jun 18;21(24):245303. doi: 10.1088/0957-4484/21/24/245303. Epub 2010 May 20.

PMID:
20484788
38.

Bone-specific growth inhibition of prostate cancer metastasis by atrasentan.

Drake JM, Danke JR, Henry MD.

Cancer Biol Ther. 2010 Apr 15;9(8):607-14. Epub 2010 Apr 4.

PMID:
20139704
39.
40.

Alumina etch masks for fabrication of high-aspect-ratio silicon micropillars and nanopillars.

Henry MD, Walavalkar S, Homyk A, Scherer A.

Nanotechnology. 2009 Jun 24;20(25):255305. doi: 10.1088/0957-4484/20/25/255305. Epub 2009 Jun 2.

PMID:
19487807
41.

Loss of alpha-dystroglycan laminin binding in epithelium-derived cancers is caused by silencing of LARGE.

de Bernabé DB, Inamori K, Yoshida-Moriguchi T, Weydert CJ, Harper HA, Willer T, Henry MD, Campbell KP.

J Biol Chem. 2009 Apr 24;284(17):11279-84. doi: 10.1074/jbc.C900007200. Epub 2009 Feb 24.

42.

Endothelin-1 inhibits prostate cancer growth in vivo through vasoconstriction of tumor-feeding arterioles.

Weydert CJ, Esser AK, Mejia RA, Drake JM, Barnes JM, Henry MD.

Cancer Biol Ther. 2009 Apr;8(8):720-9.

43.

ZEB1 enhances transendothelial migration and represses the epithelial phenotype of prostate cancer cells.

Drake JM, Strohbehn G, Bair TB, Moreland JG, Henry MD.

Mol Biol Cell. 2009 Apr;20(8):2207-17. doi: 10.1091/mbc.E08-10-1076. Epub 2009 Feb 18.

44.

Assessing siRNA pharmacodynamics in a luciferase-expressing mouse.

Svensson RU, Shey MR, Ballas ZK, Dorkin JR, Goldberg M, Akinc A, Langer R, Anderson DG, Bumcrot D, Henry MD.

Mol Ther. 2008 Dec;16(12):1995-2001. doi: 10.1038/mt.2008.187. Epub 2008 Sep 9.

45.

Chemotherapeutic agents up-regulate the cytomegalovirus promoter: implications for bioluminescence imaging of tumor response to therapy.

Svensson RU, Barnes JM, Rokhlin OW, Cohen MB, Henry MD.

Cancer Res. 2007 Nov 1;67(21):10445-54.

46.

Dystroglycan loss disrupts polarity and beta-casein induction in mammary epithelial cells by perturbing laminin anchoring.

Weir ML, Oppizzi ML, Henry MD, Onishi A, Campbell KP, Bissell MJ, Muschler JL.

J Cell Sci. 2006 Oct 1;119(Pt 19):4047-58. Epub 2006 Sep 12.

47.

Assessing tumor growth and distribution in a model of prostate cancer metastasis using bioluminescence imaging.

Drake JM, Gabriel CL, Henry MD.

Clin Exp Metastasis. 2005;22(8):674-84. Epub 2006 May 16.

PMID:
16703413
48.

Disruption of perlecan binding and matrix assembly by post-translational or genetic disruption of dystroglycan function.

Kanagawa M, Michele DE, Satz JS, Barresi R, Kusano H, Sasaki T, Timpl R, Henry MD, Campbell KP.

FEBS Lett. 2005 Aug 29;579(21):4792-6.

49.

Spiculated periosteal response induced by intraosseous injection of 22Rv1 prostate cancer cells resembles subset of bone metastases in prostate cancer patients.

Henry MD, Silva MD, Wen S, Siebert E, Solin E, Chandra S, Worland PJ.

Prostate. 2005 Dec 1;65(4):347-54.

PMID:
16032708
50.

A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer.

Henry MD, Wen S, Silva MD, Chandra S, Milton M, Worland PJ.

Cancer Res. 2004 Nov 1;64(21):7995-8001.

Supplemental Content

Loading ...
Support Center